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Background: The purpose of this study is to evaluate the ocular tolerability and efficacy of sirolimus administered
as subconjunctival or intravitreal injections in patients with non-infectious uveitis. Sirolimus as a Therapeutic
Approach for Uveitis (SAVE) is a prospective, randomized, open-label, interventional study. Thirty patients were
enrolled and randomized in 1:1 ratio to receive either intravitreal injections of 352 μg sirolimus or subconjunctival
injections of 1,320 μg at days 0, 60, and 120, with primary endpoint at month 6.
Results: At month 6, all subjects with active uveitis at baseline showed reduction in vitreous haze of one or more steps.
Forty percent of subjects showed reduction of two steps or more of vitreous haze (four in each group), and 60% showed
a reduction of one-step vitreous haze (seven in group 1 and five in group 2). Changes in the inflammatory indices were
statistically significant (p < 0.05) in both study groups. Thirty percent of patients gained one or more lines of visual acuity,
20% lost one or more lines, and 50% maintained the same visual acuity. There were no statistically significant differences
between the two study groups at month 6. No serious adverse events were found to be related to the study drug.
Conclusion: Local administration of sirolimus, either intravitreally or subconjunctivally, appears to be safe and tolerable.
No drug-related systemic adverse events or serious adverse events were noted. Sirolimus delivered as either an
intravitreal or subconjunctival injection has demonstrated bioactivity as an immunomodulatory and corticosteroid-sparing
agent in reducing vitreous haze and cells, improving visual acuity, and in decreasing the need for systemic
corticosteroids.
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Non-infectious uveitis is often of a putative autoimmune
nature, can affect patients of different age groups, and can
be limited to the eye or be part of a systemic syndrome.
Posterior uveitis, intermediate uveitis, and panuveitis are
less common than anterior uveitis, which constitutes 60%
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in any medium, provided the original work is pup to two-third of the cases [1-3]. However, posterior uve-
itis correlates more frequently with irreversible visual im-
pairment and is more challenging to manage. The triggers
of the vigorous immunologic and inflammatory responses
against ocular antigens are poorly understood, and the
mechanism by which the immune privilege is lost is yet to
be fully described. Indeed, it is well known that the ocular
autoimmune activity can be driven by lymphocytes in ei-
ther the Th1 or Th17 response [4]. The Th1 response has
been related with R14-specific T cells and with more re-
lapsing disease than seen in the Th17 response [4].an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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uveitis is to suppress inflammation and achieve remission
[5,6]. Since its first use in 1951, corticosteroids (CS) have
been the first line of treatment for non-infectious uveitis
and are the only class of drugs approved by the Food and
Drug Administration (FDA) to treat such pathology [7].
Both systemic and the local forms of CS are used to treat
posterior uveitis; not all patients, however, can tolerate
their side effects. Furthermore, satisfactory control may
not be achievable in some cases, even with the correct use
and employment of high doses of CS [7].
Immunomodulatory therapy (IMT) has become not only
a good alternative to control the inflammatory process but
also an adjunctive therapy that aids the reduction of CS
burden and their complications. While CS is usually re-
quired to control acute inflammation, IMT agents are
needed to downregulate chronic inflammation and prevent
recurrences [8]. Drugs that primarily target T-cells, like
cyclosporine and tacrolimus, have demonstrated efficacy
when employed in the treatment of uveitis [9-13]. IMT has
been employed to avoid further sequelae such as cataract,
glaucoma, proliferative vitreoretinopathy, cystoid macular
edema, vascular occlusion, and blindness [14].
Sirolimus, also known as rapamycin, was isolated in the
1970s from Streptomyces hygroscopicus in soil samples
from Easter Island [15]. Sirolimus is an immunosuppres-
sant that works through inhibition of the mammalian tar-
get of rapamycin (mTOR) by binding to the immunophilin
FK protein 12 (FKBP-12) [15], and thus interrupts the
inflammatory cascade that leads to T-cell activation and
proliferation. It also suppresses T-cell proliferation through
the inhibition of IL-2, IL-4, and IL-15 employing calcium
(Ca2+)-dependent or Ca2+-independent pathways [16,17].
Owing to its unique mechanism of action and favor-
able side effect profile, sirolimus has been increasingly
proposed as an alternative immunosuppressant in organ
transplantation. Sirolimus is the active ingredient in two
FDA-approved products, specifically RapamuneW, an im-
munosuppressive agent used in renal transplant patients,
and CYPHERW Sirolimus-eluting Coronary Stent approved
for improving coronary luminal diameter in patients with
symptomatic ischemic disease. In order to allow higher tar-
get tissue levels and reduce systemic exposure, a propri-
etary local formulation of sirolimus was developed that,
based on preclinical animal toxicity and pharmacokinetic
studies, is amenable to both intraocular (intravitreal (IVT))
and extraocular (subconjunctival (SCJ)) injection. When
administered by SCJ injection, a drug depot is formed that
subsequently dissolves slowly and diffuses across sclera
based on the physicochemical properties of sirolimus [18].
Blood levels of sirolimus after SCJ administration peaks on
day 0 to dose-dependent levels: 3.62 ng/ml for a dose of
440 μg and 9.32 ng/ml for a dose of 1,320 μg [18]. By day
7, sirolimus blood levels decrease to less than 3 ng/ml andsubsequently become minimally quantifiable, if at all, by
day 14 and beyond [18]. Following intravitreal administra-
tion, the formulation forms a non-dispersive depot in the
vitreous and localizes in the inferior portion of the vitreous
humor. The depot subsequently dissolves slowly, and
sirolimus diffuses through the vitreous humor to other
ocular layers with the highest concentration in the vitreous
followed by the retina and choroid and the lowest concen-
tration in the sclera and blood with detectable ocular tissue
levels extending for 60 days after single intravitreal admin-
istration [19]. After intravitreal administration of 352 μg,
sirolimus blood levels peak to <2 ng/ml by the second day
and decreases subsequently over the following days [18,19]
with half-life of 8 to 9 days [19]. It is also important to
recognize that the lowest therapeutic levels of sirolimus in
organ transplant and cardiac patients are 5 to 15 ng/ml
[19]. Based on the current knowledge of sirolimus and its
potential anti-inflammatory effect, we set forth to evaluate
the potential role of locally administered sirolimus in non-
infectious uveitis.
Results
Demographics and baseline characteristics
Thirty patients with a mean age of 47 (±18.8) years were
enrolled in the study. At screening, 23 of the study
participants (73%) had active uveitis, of whom 8 subjects
(23%) were not receiving any medication to control uve-
itis (disease category 1) and 15 subjects (50%) were re-
ceiving prednisone ≥10 mg/day (disease category 2).
Seven subjects (27%), including two with punctate inner
choroidopathy, had inactive uveitis at baseline and were
receiving prednisone <10 mg/day and/or other immuno-
suppressant (disease category 3). At baseline, 10 study eyes
(33%) were pseudophakic, 4 eyes had clear lens (13%), and
16 eyes had a pre-existing cataract (53%). The average
intraocular pressure (IOP) in the study eyes at baseline
was 14.7 mmHg (±3.4). Three patients (10%) had a his-
tory of bilateral glaucoma at baseline controlled with
medication; one patient had a history of bilateral tra-
beculectomy. Baseline demographics and disease char-
acteristics among study groups are summarized in
Table 1.
Outcomes at the primary endpoint (month 6)
Two subjects, one from each study group and both from
category 2, exited the study prior to the primary
endpoint at month 6. The first patient was lost to
follow-up after cataract surgery in the study eye that
was performed after receiving the second scheduled
dose of sirolimus. The second patient was lost to follow-
up following the first injection of sirolimus for personal
reasons and returned at month 6. The bioactivity data
collected from both subjects were not carried forward
to month 6, as there were significant amount of missing
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data from these two subjects were removed when com-
paring the outcome at month 6 to baseline. Adverse
events from both subjects, however, were included in
the analysis of safety outcome.Table 1 Demographics and baseline characteristics of study p









Disease category (% (n))
Category 1: active without treatment 23 (7)
Category 2: active with treatment 50 (15)
Category 3: inactive with treatment 27 (8)




Underlying disease (% (n))
Birdshot choroidopathy 13 (4)
Sarcoidosis 13 (4)
Punctate inner choroidopathy 7 (2)




Macular edema (% (n)) 37 (11)
Central macular thickness (mean ± SD) 356 ± 149
CMT in patients without ME (mean ± SD) 269 ± 28
CMT in patients with ME (mean ± SD) 505 ± 156
Corticosteroid use (% (n)) 67 (22)
Corticosteroid dose (mg/day)
Category 1 (mean ± SD) NA
Category 2 (mean ± SD) 28.2 ± 16.2
Category 3 (mean ± SD) 7.1 ± 3.0
Prior IMT use (% (n)) 25 (7)
VA in ETDRS score (Snellen equivalent)
Category 1 (mean ± SD) 62 ± 13 (20/63)
Category 2 (mean ± SD) 70 ± 17 (20/40)
Category 3 (mean ± SD) 72 ± 23 (20/40)
n, number; SD, standard deviation; CMT, central macular thickness; NA, not applicabSafety outcome
Intravitreal injections Prior to the primary endpoint at
month 6, the study eyes of group 1 received 42 intravitreal
injections of sirolimus, and the fellow eyes (from nine
patients) received 20 intravitreal injections, raising thearticipants
Intravitreal (n = 15) Subconjunctival (n = 15)
60 (9) 40 (6)
40 (6) 60 (9)
45 (±19.8) 48 (±18.2)
73 (11) 80 (12)
20 (3) 20 (3)
7 (1) -
20 (3) 27 (4)
60 (9) 40 (6)
20 (3) 33 (5)
33 (5) 27 (4)
60 (9) 60 (9)
7 (1) 13 (2)
7 (1) 20 (3)
- 27 (4)
7 (1) 7 (1)
13 (2) -
7 (1) -
67 (10) 47 (7)
47 (7) 27 (4)
377 ± 178 334 ± 116
257 ± 31.6 278 ± 22.5
515 ± 176 488 ± 134
80 (12) 67 (10)
NA NA
28.3 ± 18 27.9 ± 14.9
7.3 ± 2.1 7.0 ± 4.0
20 (3) 27 (4)
55 ± 6.2 (20/80) 68 ± 15.4 (20/40)
66 ± 16.8 (20/50) 75 ± 18.9 (20/32)
66 ± 23.1 (20/50) 75 ± 24.2 (20/32)
le; VA, visual acuity; ME, macular edema.
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injections. The adverse events encountered with intra-
vitreal injections of sirolimus were rare and scattered. The
most commonly reported adverse event in this group was
vitreous floaters. Other ocular adverse events included
single instances of changed refraction resulting in blurred
vision, post-injection subconjunctival hemorrhage, fore-
head rash (above the study eye), ocular pain and redness,
and progression of pre-existing cataract and glaucoma
that required combined cataract extraction and glaucoma
surgery with Ahmed valve implantation in the study eye.
The ocular pain, redness, and subconjunctival hemorrhage
were all considered related to the injection procedure ra-
ther than sirolimus. No other ocular adverse event was
considered related to either the injection procedure or the
study drug. Systemic adverse events included one event
each of upper respiratory infection, tooth abscess, and sci-
atic pain secondary to disc prolapse. No systemic adverse
event was considered related to the study drug. All sys-
temic and ocular adverse events in this group were mild
to moderate in severity and resolved without sequelae.
The average IOP in the study eyes was 15.5 mmHg (±3.3)
at baseline, 14.7 mmHg (±3.8) at day 60, 15 mmHg (±3.9)
at day 120, and 13.1 (±2.9) at month 6. With the exception
of one patient, all other study subjects had IOP <25 mmHg
throughout the study.
Serious ocular adverse events included the development
of rapidly progressing cataract in a study eye that resulted
in a loss of visual acuity ≥6 Early Treatment Diabetic Ret-
inopathy Study (ETDRS) lines and in cataract extraction
surgery prior to day 90. The patient was lost to follow-up
after the surgery and dropped out of the study. Serious ad-
verse events also included an instance of loss of visual
acuity ≥6 ETDRS lines in a fellow eye because of persist-
ent elevation of IOP ≥35 mmHg for more than 2 weeks.
In this particular patient, the fellow eye did not meet the
inclusion criteria of the Sirolimus as a Therapeutic Ap-
proach for Uveitis (SAVE) Study initially because of
elevated IOP (36 mmHg) despite maximal medical con-
trol. During the course of the study, the patient refused to
receive the standard of care with local therapy for the fel-
low eye and hence sirolimus was provided to this eye
when the IOP was controlled to <25 mmHg. Following
day 74, recurrence of ocular hypertension and worsening
of the cataract resulted in a loss of ≥6 lines of visual acuity.
Combined cataract extraction and glaucoma surgery with
Ahmed valve was done electively, and prednisone was
increased postoperatively to the baseline level (30 mg/
day). The former case of ocular serious adverse events
(SAEs), with rapidly progressing cataract, was considered
possibly related to the study drug, although traumatic
cataract secondary to the injection procedure was also
entertained as a possibility. The latter SAE with ocular
hypertension requiring glaucoma surgery in the fellow eyewas considered unlikely related to the study drug and
more likely related to the course of the disease that may
have led to worsening of the uveitic glaucoma.
Subconjunctival injections Subjects enrolled in group
2 received a total number of 66 subconjunctival injections
of sirolimus prior to month 6, 44 to the study eyes and 22
to the fellow eyes (from ten patients). The most commonly
encountered adverse events were inflammation at the in-
jection site; seven instances (10%) in six patients (40%).
The inflammation manifested as ocular pain and localized
tenderness and hyperemia overlying the subconjunctival
aggregate of sirolimus (Figure 1). The inflammations were
mild to moderate, peaked at 2 weeks after injection, re-
solved spontaneously without sequelae within additional 2
weeks, and were considered likely related to the study
drug. Other ocular adverse events included vitreous
floaters (two instances in the same patient) and single
instances of transient loss of vision in a study eye for
about 60 min and of progression of a pre-existing cata-
ract in a fellow eye, which required cataract surgery.
Average IOP in the study eyes was 13.8 mmHg (±3.3)
at baseline, 13.8 mmHg (±3.9) at day 60, 13.6 mmHg
(±3.2) at day 120, and 15.3 (±4.6) at month 6. None of the
study participants in this group had an IOP >25 mmHg
throughout the study.
Systemic adverse events included single instances of
back pain, broken wrist secondary to fall, upper respira-
tory and urinary tract infections, a probable diagnosis of
Crohn's disease on colonoscopy, and vascular surgery of
lower extremity secondary to complications of diabetes
mellitus. With the exception of the injection site inflam-
mation, all ocular and systemic adverse events were mild
to moderate in nature, and none was considered to be
related to the study drug. No serious adverse events were
observed in this group of patients. None of the study
participants, in either injection group, met any of the res-
cue criteria prior to the primary endpoint at month 6.
Therefore, no study subjects received rescue
treatment.
Bioactivity outcome
Changes in the inflammatory indices Summary of the
inflammatory indices at baseline and the changes at
months 3 and 6 are shown in Table 2.
Study categories 1 and 2 (active uveitis at baseline,
n = 20) At month 3, 12 subjects (60%) showed a reduc-
tion of two steps or more of vitreous haze (six in each
group), and 8 subjects (40%) showed either no change or a
reduction less than two steps (five in group 1 and three in
group 2). At month 6, 8 subjects (40%) showed a reduc-
tion of two steps or more of vitreous haze (four in each
Figure 1 Color slit-lamp photographs of a patient with conjunctival inflammation following subconjunctival injection of sirolimus.
Significant chemosis along with conjunctival hyperemia overlying the whitish subconjunctival aggregate of the study drug can be seen.
Table 2 Changes from baseline in inflammatory indices, dose of corticosteroids, and visual acuity
All (n = 28) Group 1 (n = 14) Group 2 (n = 14)
Baseline Month 3 Month 6 Baseline Month 3 Month 6 Baseline Month 3 Month 6
Anterior chamber cells (number of patients)
None 24 26 27 11 13 14 13 13 13
0.5+ 3 2 1 2 1 - 1 1 1
1+ 1 - - 1 - - - - -
2+ - - - - - - - - -
3+ - - - - - - - - -
4+ - - - - - - - - -
Vitreous cells (number of patients)
None 14 22 27 8 11 11 6 11 11
0.5+ 5 5 1 3 3 2 2 2 1
1+ 7 1 - 3 - 1 4 1 2
2+ 2 - - - - - 2 - -
3+ - - - - - - - - -
4+ - - - - - - - - -
Vitreous haze (number of patients)
None - 13 7 - 6 3 - 7 4
0.5+ 8 11 16 3 6 9 5 5 7
1+ 11 4 5 7 2 2 4 2 3
2+ 8 - - 3 - - 5 - -
3+ 1 - - 1 - - - - -
4+ - - - - - - - - -
Corticosteroids dose (median mg/day ± SD)
Category 1 (n = 7) NA NA NA NA NA NA NA NA NA
Category 2 (n = 13) 20 ± 15.7 12.5 ± 6.8 8 ± 5.7 25 ± 18.1 13.8 ± 8 7.8 ± 7.1 20 ± 11.4 12.5 ± 4.5 8.0 ± 1.9
Category 3 (n = 7) 9 ± 3.1 4 ± 2.9 3 ± 2.2 8.0 ± 2.1 4.0 ± 2.5 3.0 ± 1.8 9.0 ± 4.0 5.5 ± 3.5 3.0 ± 2.6
Visual acuity (mean ±SD)
Category 1 62 ± 13.3 66 ± 13.1 61 ± 14.5 55 ± 6.2 59 ± 12.7 51 ± 10.6 68 ± 15.4 72 ± 11.5 69 ± 12.8
Category 2 71 ± 16.8 72 ± 16.3 72 ± 18.1 69 ± 15.3 70 ± 14.4 69 ± 16.9 73 ± 20.6 77 ± 20.1 76 ± 21.3
Category 3 72 ± 22.6 74 ± 18.3 74 ± 15.8 66 ± 23.1 71 ± 16.3 69 ± 14 75 ± 24.2 77 ± 21 76 ± 17.8
n, number; SD, standard deviation; NA, not applicable.
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a reduction of one-step vitreous haze (seven in group 1
and five in group 2). No patient in either category showed
increase of vitreous haze of one or more steps at either
month 3 or month 6.
The reduction in vitreous haze at month 3 and month 6
was statistically significant, when assessed using Wilcoxon
signed rank test with p < 0.05, in both treatment groups
and at both time points. The difference in the vitreous
haze outcome between treatment groups (intravitreal vs
subconjunctival) was not statistically significant, either at
month 3 or month 6 (p = 0.901 and 0.727, respectively),
when assessed by Mann–Whitney U test.
Comparing the outcome of both categories at month 3,
71% of subjects in category 1 (5/7, two in group 1 and
three in group 2) showed a reduction of ≥2 steps of vitre-
ous haze compared to 54% in category 2 (7/13, four in
group 1 and three in group 2). Meanwhile, 29% of subjects
in category 1 (2/7, one in each group) showed either no
change or a reduction <2 steps compared to 46% in cat-
egory 2 (6/13, four in group 1 and two in group 2).
Comparing both categories at month 6, 57% of subjects
in category 1 (4/7, two in each group) showed a reduction
of ≥2 steps of vitreous haze compared to 31% in category 2
(4/13, two in each group). Meanwhile, 43% of subjects in
category 1 (3/7, one in group 1 and two in group 2) showed
either no change or a reduction <2 steps compared to 69%
in category 2 (9/13, six in group 1 and three in group 2).
Study category 3 (inactive uveitis at baseline, n = 8)
Patients in category 3 did not show statistically signifi-
cant changes in vitreous haze in any of the study groups
at either month 3 or month 6 (p = 0.317 at month 6,
Wilcoxon signed rank test).
Response to treatment In patients with active uveitis at
baseline (disease categories 1 and 2), eight subjects (40%,
four from group 1 and four from group 2) achieved
complete response to treatment (reduction of vitreous
haze by two steps or more or reduction of one step to
no haze) at the primary endpoint at month 6. Four sub-
jects (60%) showed either no change in vitreous haze or
a reduction in vitreous haze of no more than one step.
No patient showed worsening of vitreous haze at month
6 in these categories (Figure 2).
In category 3 (patients with inactive uveitis at base-
line), seven subjects (88%) maintained stable vitreous
haze at month 6 (three from group 1 and four from
group 2), with four patients demonstrating no change in
vitreous haze (two from each group) and three patients
(one from group 1 and two from group 2) demonstrating
a reduction of one step (0 vitreous haze). One patient
(12%) in this category showed an increase of vitreous
haze of one step at month 6 (group 2).Corticosteroid sparing effect Twenty subjects were re-
ceiving systemic CS at baseline, 13 in category 2 (pred-
nisone ≥10 mg/day) and 7 in category 3 (prednisone
<10 mg/day and/or IMT). Prior to screening, 7 subjects
were receiving immunosuppressants other than CS (IMT);
two subjects were receiving their IMT in conjunction with
a prednisone dose <10 mg/day, four subjects were receiv-
ing IMT in conjunction with prednisone ≥10 mg/day,
and one subject was receiving IMT as a maintenance
monotherapy.
Table 2 and Figure 3 demonstrate the changes in the
median dose of CS among the study group and categor-
ies. In category 2, the median dose was 20 mg/day and
was reduced to 12.5 mg/day at month 3 and to 8 mg/
day at month 6. The dose was reduced to less than 10
mg/day in two patients (one from each group) before
month 3, and by month 6, the CS dose was successfully
reduced to less than 10 mg/day in 11 subjects (six from
group 1 and five from group 2). It was not possible to
reduce the CS dose to less than 10 mg/day in two
patients (both in group 1). The CS was reduced, how-
ever, from 50 mg/day at baseline to 15 mg/day at month
6 in one patient and from 30 mg/day to 25 mg/day in
the other (the dose was initially reduced to 10 mg/day at
day 74; however, it was raised to 30 mg/day in the peri-
operative period of bilateral combined cataract extractions
and Ahmed valve implantation).
The median dose of CS in category 3 was reduced
from 9 mg/day at baseline to 4 and 3 mg/day at months
3 and 6, respectively.
Changes in visual acuity The average visual acuity (VA)
at baseline was 69 (±17.7) letters (equivalent to 20/40).
The average VA was 62 (±13) letters, 70 (±17) letters, and
72 (±23) letters in categories 1, 2, and 3, respectively
(Table 2). At month 3, ten subjects (36%) gained one or
more lines of VA (three in group 1 and five in group 2).
Of the ten patients, four patients gained two lines, and
one patient gained three lines (all in group 2). Four pa-
tients (14%) lost one line of VA at month 3 (two in each
group). Fourteen subjects (50%) did not show any changes
in VA at month 3.
At month 6, 11 subjects (39%) gained one or more
lines of VA (five in group 1 and six in group 2). Of the
11 patients, 3 gained two lines (all in group 2) and 1
gained 3 lines (group 1). Six patients (21%) lost one or
more lines at month 6 (three in each group) with three
patients losing two lines (one in group 1 and two in group
2) and with one patient losing three lines of VA (group 2).
Eleven subjects (39%) did not show any changes in VA at
month 6.
In all study groups and categories, there was a trend in
gain of VA at month 3 that was maintained at month 6
in all categories of injection groups except in patients in
Figure 2 Change in vitreous haze at months 3 and 6 in patients with active uveitis at baseline.
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where the initial gain of VA at month 3 was lost or even
reversed at month 6 (Figure 4).
Central macular thickness At baseline, 37% of subjects
had macular edema (n = 11, seven in group 1 and four
in group 2), with an average central macular thickness
(CMT) of 505 μm (±156) on spectral domain opticalFigure 3 Changes in dose of corticosteroids maintained by the patiencoherence tomography (OCT). CMT in patients without
macular edema (n = 17) did not show changes from
baseline in any patient, either at month 3 or at month 6,
with an average thickness of 272 μm (±27 μm), 266 μm
(±27 μm), and 265 μm (±29 μm) at baseline, month 3,
and month 6, respectively.
In patients with ME at baseline, CMT decreased in
group 1 from an average of 510 μm (±194 μm) atts at month 3 and month 6.
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increased to 615 μm (±168 μm) at month 6 (Figure 5), a
mean change of −75 and 105 μm at months 3 and 6, re-
spectively. Group 2 showed reduction of CMT from 481
μm (±131 μm) at baseline to 448 μm (±74 μm) at month 3
and 451 μm (±114 μm) at month 6, a mean change of −33
and −30 μm at months 3 and 6, respectively.
At month 3, six patients (three in group 1 and two in
group 2) showed significant reduction of CMT with two
patients (both in group 1) showing complete resolution
of macular edema (Figure 6). However, at month 6, only
two patients continued to show reduction in CMT;
CMT increased to its baseline level in two other patients
and significantly increased in the last two (both had
complete resolution at month 3; Figure 6).
Two patients showed steady increase in CMT at both
month 3 and month 6, and three patients did not show
significant changes in CMT either at month 3 or month 6.
Fellow eyes At baseline, 12 fellow eyes had active uveitis
(four in category 1 (33%) and eight in category 2 (67%));
16 had inactive uveitis. At the primary endpoint at
month 6, 79% (19/28) of the fellow eyes received at least
one sirolimus injection, subconjunctival or intravitreal
(with a total of 42 injections); 7 fellow eyes (44%), which
were inactive at baseline, had flare-ups of uveitis that
were treated with sirolimus during the course of the
study with tapering of the CS. Thirty-eight percent (16/
42) of the injections to the fellow eyes were administeredFigure 4 Changes in mean visual acuity among different categories o
retinopathy study.during the period from day 0 to month 2, 36% (15) be-
tween months 2 and 4, and 28% (11) between months 4
and 6.
None of the fellow eyes received any other form of
intra- or peri-ocular injections other than sirolimus. Dur-
ing the specified period, the fellow eyes received 12
injections in category 1 (1.7 injections per patient), 13 in-
jections in category 2 (1 injection per patient), and 15
injections in category 3 (1.9 injections per patient).
Quality of life Mean scores were calculated for each of
the subcategories and for total score at baseline and
month 6 (Table 3). The change in the overall visual func-
tion questionnaire (VFQ) score demonstrated statistical sig-
nificance at month 6 compared to baseline (p < 0.05). Six of
12 subcategories demonstrated significant improvements in
their mean VFQ scores at month 6 compared to baseline.
There was a statistically significant improvement in the
general vision, ocular pain, distance activities, visual mental
health, visual role difficulties, and visual dependency
subcategories.
Mean total VFQ scores were calculated at baseline and
month 6 and stratified by disease activity (Table 4).
There was a significant improvement in mean VFQ
score in the subconjunctival group. The intravitreal in-
jection group demonstrated an improvement in VFQ
scores; however, the results had borderline significance
(p = 0.09). Subjects in category 1 had lower baseline
scores than the other two groups. Although this groupf study groups at months 3 and 6. ETDRS, early treatment diabetic
Figure 5 Changes in mean central macular thickness from baseline. Patients with macular edema at months 3 and 6 in different
study groups.
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results had borderline significance (p = 0.057). Subjects
in category 2 demonstrated a significant improvement in
scores (p = 0.027), while category 3 demonstrated non-
significant improvement in score (p = 0.221).
Discussion
Through its mechanisms of action, sirolimus inhibits the
production, signaling, and activity of many growth factors
and antibodies relevant to uveitis by a mechanism that is
distinct from that of other immunosuppressants. Sirolimus
has also been shown to downregulate the expression of
many genes related to inflammation such as interleukin-8,
endothelial monocyte-activating polypeptide II, granulocyte
chemotactic protein 2, cyclooxygenase 1 and 2, and indu-
cible nitric oxide synthase [20-23].
IMT has been shown to be useful in the management of
uveitis while reducing the need for CS. Despite the appar-
ent usefulness of systemic IMT in the management of
uveitis, bone marrow suppression, neurotoxicity, nephro-
toxicity, hepatitis, pneumonitis, diarrhea, infertility, and
secondary malignancy are potential side effects that limit
the use of such agents and require individualization and
close monitoring of IMT [9].
Shanmuganathan and colleagues evaluated systemic
sirolimus as an alternative treatment for severe non-
infectious uveitis refractory to other drugs or requiring
local injections or high doses of systemic CS. Sirolimus
was effective as a corticosteroid-sparing drug in five ofeight patients; in the other three patients, the side effects
were intolerable or the drug failed to control uveitis [24].
In a retrospective study, Phillips and Wroblewski re-
ported a case series of eight patients with severe uveitis
who were treated with oral, low-dose sirolimus (1 to 4
mg/day). Out of the eight patients, three patients showed
improvement of uveitis when sirolimus was given in ad-
junction with oral methotrexate, and one patient showed
improvement with sirolimus monotherapy. The study was
called a failure after serious side effects forced discontinu-
ation of sirolimus therapy [25].
Although the class of mTOR inhibitors seems to be
relatively well tolerated and offers exciting new thera-
peutic opportunities in different disorders, they are ac-
companied also by local and systemic side effects and
adverse events. Systemic use of sirolimus has been asso-
ciated with mucositis, skin rashes, pulmonary toxicity,
hyperglycemia, and bone marrow toxicity among other
toxicities including hepatobiliary disorders [26], epider-
mal and dermal conditions such as squamous and basal
cells carcinomas and photosensitivity [26], infections
[27], and renal [27] and respiratory disorders [26,28].
The frequent adverse events of the mTOR inhibitors are
hematological, especially microcytic anemia, leukopenia,
and thrombocytopenia [29-33]. It was recently argued
that low-dose oral sirolimus increases the risk of
menstrual-cycle disturbances and ovarian cysts. It was
also postulated that monitoring of sirolimus-associated
ovarian toxicity is warranted and might guide clinical
Figure 6 Spectral domain optical coherence tomography horizontal scans and thickness maps at various study time points. Two study
subjects presented with macular edema at baseline. Both patients had posterior uveitis at baseline and were randomized to group 2
(subconjunctival group). At baseline, subject 5 had active uveitis and was receiving no systemic immunosuppressants (study category 1). Subject
23 had active uveitis at baseline and was receiving prednisone 20 mg/day (study category 2); the prednisone dose was tapered to 15 mg/day at
month 3 and to 7.5 mg/day at month 6. Sirolimus was injected at days 0, 60, and 120 (yellow asterisks). Noticeable reduction in macular edema
and central macular thickness was consistently observed 14 to 30 days following the injection with diminished response observed in the visits
following day 120.
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temic morbidities associated with immunosuppressants,
either CS or IMT, have encouraged the conduct of clinical
trials that aimed at the development of local therapies that
can be used in controlling uveitis while minimizing the
potential side effects. In a 3-year multicenter clinical trial,
the fluocinolone acetonide intravitreal implant showed
control of uveitis with significant reduction of recurrences
in the implanted eyes along with improvement or sta-
bilization of visual acuity. The implanted eyes, however,
had higher risk of increased intraocular pressure that
required glaucoma filtering surgery (attributable risk of
38%) and of cataract surgeries (attributable risk of 73% on
previously phakic eyes). The FA implants certainly can
provide an alternative approach for prolonged control of
inflammation in non-infectious uveitis. Nevertheless, its
usage may not be possible in all situations because of themorbidities associated with such therapy [35]. Intravitreal
formula of methotrexate was also evaluated in a prospect-
ive study for the treatment of uveitis and uveitic cystoid
macular edema. Fifteen eyes from 15 patients with a unilat-
eral exacerbation of non-infectious uveitis received single
intravitreal injection of 400 μg methotrexate. The treated
eye showed significant improvement of VA and reduction
of the inflammatory indices in 80% of the injected eyes with
reduction of the CS dose in some of the study participants
who were receiving CS therapy at baseline. One third of the
patients relapsed after a median of 4 months [36].
In our study, both intravitreal and subconjunctival
injections of sirolimus were well tolerated. The most
encountered adverse event was inflammation at the in-
jection site manifesting as conjunctival hyperemia and
chemosis in patients who received sirolimus subcon-
junctivally. Such result is consistent with recent reports
Table 3 VFQ-39 subcategory scores and mean total score
stratified by date of examination
VFQ subcategory Baseline Month 6 Difference P value
General health 66.20 68.80 2.59 0.428
General vision 63.52 70.37 6.85 0.010
Ocular pain 70.83 81.94 11.11 0.013
Near activities 73.21 74.55 1.34 0.607
Distance activities 75.43 81.48 6.05 0.026
VS social functioning 87.35 91.98 4.63 0.100
VS mental health 57.50 69.26 11.76 0.000
VS role difficulties 69.21 76.39 7.18 0.035
VS dependency 79.40 88.19 8.80 0.045
Driving 70.31 74.65 4.34 0.069
Color vision 90.74 95.37 4.63 0.232
Peripheral vision 78.70 83.33 4.63 0.289
Total VFQ score 72.33 79.44 7.11 0.001
P values were calculated using Student's t test. VS, versus.
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those reported when locally administered sirolimus was
investigated in diabetic macular edema [18,37]. The de-
velopment of cataract in two study eyes and one fellow eye
in the intravitreal group was considered incidental or sec-
ondary to the progression of the primary disease and not
necessarily related to the study drug. In the first cataract
case, there was a suspicion that the cataract was the result
of a traumatic effect of the injection procedure; however,
no track marks were observed at the back of the lens. The
other two cataract surgery incidents occurred in a single
patient who had a pre-existing cataract and glaucoma. It is
difficult to ascertain if sirolimus has contributed to the pro-
gression of cataract and glaucoma in this particular patient,
especially in the fellow eye, which already had cataract and
glaucoma refractory to maximal medical therapy. Other
than these two patients, no other patients developed new
cataract or had significant worsening of a preexisting one.
Previous studies of intravitreal [18] and subconjunctival
[18,37] injection of sirolimus also did not show significantTable 4 VFQ-39 total scores stratified by visits, treatment
type, and disease activity
Baseline Month 6 Difference P value
Treatment type
Group 1 73.59 78.08 4.49 0.090
Group 2 71.16 80.71 9.54 0.005
Disease activity
Category 1 57.95 69.24 11.28 0.057
Category 2 77.09 83.78 6.69 0.027
Category 3 77.77 81.87 4.09 0.2209
P values were calculated using paired t test.changes in the lens condition, and there were no reports of
required cataract surgeries [18,37].
Although systemic adverse events were infrequent in
our study, it is important to mention that identifying ad-
verse events during the course of a clinical trial might be
subjected to several pitfalls and biases. In our study, the
small study sample, short follow-up period, under repre-
sentation of some populations, and lack of extensive la-
boratory and systemic assessments may have limited our
ability to detect some systemic adverse events that may
have occurred. On the other hand, despite local therapy
is generally preferred, the frequent clinic visits to deliver
treatment, the risks associated with intravitreal injec-
tions such as sight-threatening endophthalmitis, the ne-
cessity to treat both eyes separately in cases of bilateral
uveitis, which may further increase the frequency of
clinic visits if both eyes are to be injected in separate
sessions, and the absence of systemic benefits in patients
with extra-ocular manifestations of autoimmune disease
are all limitations that should not be overlooked while
calculating the risk/benefit ratio of locally delivered
drugs for management of non-infectious uveitis.
In the SAVE Study, the first study to evaluate subcon-
junctival and intravitreal delivery of sirolimus for inter-
mediate, posterior, or panuveitis, 40% of patients with
active uveitis at baseline (categories 1 and 2) showed im-
provement of two steps or more of vitreous haze, as
measured using the Standardized Uveitis Nomenclature
(SUN) working group criteria, and 60% of patients showed
either no change from baseline or one-step reduction of
vitreous haze. The reduction in vitreous haze at the pri-
mary endpoint was statistically significant in both study
groups (p < 0.5). In this study, no significant differences in
response profile were detected based on route of delivery,
i.e., both study groups were equally responsive to treat-
ment. The improvement in the inflammatory indices in
category 2 was associated with reduction of the adjunct
corticosteroid dose in all patients (n = 13) with the major-
ity (85%) of patients successfully tapered to less than 10
mg/day of CS at month 6. The improvement in the in-
flammatory indices of category 1 was achieved without
the use of CS at any time point during the study. Overall,
88% of the patients with inactive uveitis at baseline (cat-
egory 3) maintained the quiescence of uveitis at month 6
while the corticosteroid dose was successfully tapered in
all patients with a median reduction of 6 mg/day (from 9
to 3 mg/day) by month 6. As the inclusion criteria for cat-
egories 1 and 2 did not require enrolled patients to have
2+ or more vitreous haze, not all enrolled subjects had the
potential to improve two or more steps. As an exploratory
study, SAVE was designed to evaluate any potential effi-
cacy of sirolimus in uveitis, and thus allowed entry of ≥1+
vitreous haze. Nevertheless, 40% of subjects showed com-
plete response to sirolimus injections.
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provement of VA at month 6 with half of the study
participants showing visual stability and 20% losing one or
more lines of VA. The VA at baseline was quite good and
hence allowed lesser potential for significant visual gain.
In patients who had macular edema at baseline (n = 11),
there was initial reduction of central macular thickness at
month 3 in about half of the patients (n = 6). However,
such reduction in macular thickness at month 3 has
continued at month 6 only in two patients out of the 6
and was maintained in another two. The relative wor-
sening of macular edema at month 6, when compared to
month 3, could be explained by the longer interval be-
tween treatments and measuring of the macular thickness
at month 6, when compared to month 3, which implies
that a higher dose and/or more frequent injections of
sirolimus may be necessary to achieve and maintain satis-
factory outcomes.
Patients in our study also have shown improvement of
their quality of life as evidenced by the responses on VFQ-
25. The visual functioning questionnaire revealed statis-
tically significant improvement in the overall outcome
(p < 0.5) with significant improvements in 6 of the 12 sub-
categories of the test. As may be expected, patients with
inactive uveitis at baseline showed the least improvement
(p = 0.22). After the discontinuation of systemic IMT for
the study subjects to be enrolled in the SAVE Study and
the tapering of CS, the elimination of being fatigue and
suffering from adverse events has most likely contributed
to the improvement in the quality of life for the patients.
Conclusions
In conclusion, the SAVE Study has provided informative
and valuable insights toward the goals of identifying
effective local therapy for uveitis and ocular inflamma-
tory diseases. Local administration of sirolimus, either
intravitreally or subconjunctivally, appears to be well tol-
erated in patients with non-infectious uveitis. Sirolimus
delivered either intravitreally or subconjunctivally has
demonstrated bioactivity as an IMT and corticosteroid-
sparing agent in reducing vitreous haze and cells and im-
proving VA. Long-term outcomes, beyond 6 months, and
additional phase 2 and 3 clinical trials, which are being
conducted in the USA and other countries, are warranted
to confirm the role of locally delivered sirolimus as an
immunomodulatory therapeutic agent and to determine
its appropriate dosage and frequency of treatments.
Methods
SAVE is a proof-of-concept, open-label, randomized clin-
ical study conducted at the Wilmer Eye Institute, Johns
Hopkins University School of Medicine (Baltimore, MD,
USA) to assess the safety, tolerability, and bioactivity of
intravitreal and subconjunctival injections of sirolimus inpatients with non-infectious uveitis. The study was
approved by the Johns Hopkins University Institutional
Review Board and was conducted in compliance with the
Declaration of Helsinki, US Code of Federal Regulations
Title 21, and the Harmonized Tripartite Guidelines for
Good Clinical Practice (1996). Before screening, all the
subjects involved in the SAVE Study reviewed and signed
informed consent. The SAVE Study is registered at
ClinicalTrials.gov (identifier: NCT00908466).
Consented patients with non-infectious intermediate,
posterior, and panuveitis were screened for the study.
Enrolled patients were stratified at baseline into three
categories: (1) active disease and receiving no treatment,
(2) active disease and receiving prednisone ≥10 mg/day
(or equivalent dose of another CS) and/or at least one
other systemic immunosuppressant, and (3) inactive dis-
ease and receiving prednisone <10 mg/day (or equivalent
dose of another CS) and/or at least one other systemic
immunosuppressant.
In the SAVE Study, active disease was defined as having
at least 1+ vitreous haze, using the SUN Working Group/
National Eye Institute - Nussenblatt scale [38,39]. Inactive
disease was defined as having vitreous haze of 0.5+ or less
and vitreous cell count of 0.5+ or less, using the SUN
Working Group/National Eye Institute (NEI) scale [38,39].
All IMT agents were discontinued at least 30 days prior to
the first administration of the study drug at day 0. Patients
who were not receiving CS at screening were not allowed
to receive any CS in the interim 30-day period prior to day
0. Systemic CS therapy at baseline was allowed to continue
for patients who were already receiving CS therapy. Sys-
temic CS was tapered immediately upon initiation of the
first dose of sirolimus. For patients in category 2, the aim
was to reduce the dose of CS to <10 mg/day. For patients
in category 3, the aim was to discontinue CS or to reduce
the dose to less than 5 mg/day.
Patients in each category were randomized in a ratio of
1:1 into one of two treatment groups; group 1 received
intravitreal injections of sirolimus in a dose of 352 μg, and
group 2 received subconjunctival injections of sirolimus in
a dose of 1,320 μg. Three mandatory injections of either
subconjunctival or intravitreal of sirolimus were given at
days 0, 60, and 120. Follow-up visits were scheduled at 14
and 30 days (±2 days) after each injection. The primary
endpoint of the SAVE Study was set at month 6. Patients
are being monitored up to month 12. During the period
from month 6 to month 12, patients with residual or re-
current uveitic activity are allowed to receive additional
treatments with sirolimus up to every 2 months leading to
a maximum of six injections over the 12-month study
duration. Only the primary endpoint results at 6 months
for the study eyes are being reported in this manuscript.
The eligibility inclusion and exclusion criteria are listed in
an online supplement (Additional file 1: Table S1).
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In patients with bilateral uveitis, the eye with more
advanced disease was chosen as the study eye. If both eyes
were equally affected, the study eye was chosen at the
investigator's discretion prior to randomization. If the
standard-of-care local therapies to the fellow eye were
contraindicated, proved ineffective, or refused by the pa-
tient, then sirolimus injections were administered to the
fellow eye at the investigator's discretion and at the same
dose and route of administration of the study eye, but at
least 14 days apart from the study eye injection.
Administration of study drug
Sirolimus is formulated as clear, non-aqueous solutions in
a vehicle composed of polyethylene glycol 400 (PEG 400)
and ethanol (200 proof). Both PEG 400 and ethanol are
widely used solubilizing excipients in injectable formu-
lations [40]. Sirolimus was supplied frozen as 0.5 ml of
sterile injectable solution in 2.0 ml vials. Once the admin-
istration route was determined for a patient, a vial of
sirolimus was removed from the freezer and thawed by
rotating the vial between the palms of the hands for a mini-
mum of 5 min or by setting the vial at room temperature
for a minimum of 30 min. Topical anesthesia and antisep-
tic measures were performed prior to injection employing
standard procedures. A 30-gauge needle was used on a
Hamilton glass syringe to deliver the intravitreal injections
and on tuberculin syringe to deliver the subconjunctival
injections. Sirolimus injections were performed within 2
hours following the removal of the drug from the freezer.
Rescue therapy was allowed for all participants at any time
when one or more of pre-defined rescue criteria is met
(Additional file 2: Table S2).
In addition to ophthalmological assessment at each
study visit (for the study flow chart and procedures done
at each visit, please refer to Additional file 3: Table S3),
changes in quality of life were assessed using the
extended VFQ-25. The extended VFQ-25 (consisted of
39 questions) was developed by the NEI to measure self-
reported vision health status in patients with chronic eye
disease [41]. The questionnaire assesses the effects of
visual impairment on both task-oriented domains related
to visual function and general health domains such
as emotional well-being and social functioning. Each
patient's questionnaire was converted to a scaled score
between 0 (worst) and 100 (best) using the VFQ-25
Scoring Algorithm version 2000 [42]. Individual question
scores were combined into the different subcategories as
detailed in the Scoring Algorithm.
Data collection and management
The Retinal Imaging Research and Reading Center
(RIRRC) at the Wilmer Eye Institute served as the co-
ordinating, data management, and reading Center forthe SAVE Study. Readers in the RIRRC were masked to
treatment groups.
Study endpoints and statistical analyses
The main outcomes were the bioactivity and ocular tol-
erability of intravitreal and subconjunctival injection of
sirolimus in the treatment of non-infectious uveitis. The
primary bioactivity analysis was conducted at month 6
and was evaluated by assessing the proportion of pa-
tients achieving a complete or partial response in the
study eye. Complete response was defined as reduction
of vitreous haze by at least two steps when compared to
baseline or reduction of a single step to no haze. Partial
response was defined as improvement of vitreous haze
of no more than one step. In patients with inactive dis-
ease at baseline (category 3), success (or efficacy) of treat-
ment was assessed by the proportion of patients who
maintained quiescent uveitis throughout the 6-month
period of the study while tapering or discontinuing their
previous CS therapy. In addition, the activity of disease
in two patients with punctate inner choroidopathy, both
enrolled in category 3, was also monitored by fluores-
cein angiography and high-resolution spectral domain
OCT, as both had ≤0.5+ vitreous haze at the time of
enrollment.
The secondary bioactivity endpoint was defined as the
ability of sirolimus to reduce or prevent flare-up of uve-
itis in the study eye (as expressed by the frequency of
ocular attacks during the first 6-month period) as
evidenced by increase in vitreous haze and cells and an-
terior chamber cells when compared to previous visits.
Other secondary parameters included change from base-
line in best-corrected visual acuity as measured by
ETDRS charts and in macular thickness as measured by
spectral domain OCT.
The safety and tolerability of subconjunctival and
intravitreal injection of sirolimus in patients with inter-
mediate, posterior, and panuveitis were evaluated by
assessing the incidence of systemic and ocular adverse
events, study drug related adverse events, severe adverse
events, and serious adverse events, through intraocular
pressure measurements, physical examinations, liver func-
tion tests, and other serologic markers. Baseline demo-
graphics and disease characteristics were summarized
(number and percentage for categorical measures and
number, mean, standard deviation, and median for con-
tinuous measures) by treatment group and by disease cat-
egory within treatment group. Non-parametric statistical
tests, e.g., Wilcoxon signed rank test and Mann–Whitney
test, were employed to assess the significance of changes
from baseline in vitreous haze among the different cat-
egories of study groups at month 3 and month 6. Signifi-
cance of changes from baseline in VFQ was determined
using paired t test. The statistical analysis was run using
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